MX364280B - Compuestos utiles para tratar envejecimiento prematuro y en particular progeria. - Google Patents

Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.

Info

Publication number
MX364280B
MX364280B MX2015016292A MX2015016292A MX364280B MX 364280 B MX364280 B MX 364280B MX 2015016292 A MX2015016292 A MX 2015016292A MX 2015016292 A MX2015016292 A MX 2015016292A MX 364280 B MX364280 B MX 364280B
Authority
MX
Mexico
Prior art keywords
group
alkyl
premature aging
hydroxyl
compounds useful
Prior art date
Application number
MX2015016292A
Other languages
English (en)
Inventor
Mahuteau Florence
Najman Romain
Tazi Jamal
Scherrer Didier
Santo Julien
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09162630A external-priority patent/EP2261214A1/en
Priority claimed from EP20090305540 external-priority patent/EP2266972A1/en
Application filed by Abivax filed Critical Abivax
Publication of MX364280B publication Critical patent/MX364280B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto (I) en donde: significa un grupo piridazina, pirimidina o pirazina, R independientemente representa un átomo de hidrógeno, átomo de halógeno o un grupo seleccionado de entre un grupo -CN, un grupo hidroxilo, un grupo -COOR1, un grupo fluoroalquilo de C1-C3, un grupo fluoroalcoxi de C1-C3, un grupo -NO2, un grupo -NriR2, un grupo alcoxi de C1-C4, un grupo fenoxi, y un grupo alquilo de C1-C3, el alquilo opcionalmente mono-sustituido por un grupo hidroxilo, n es 1, 2 o 3, n´ es 1 o 2, R´ es un átomo de hidrógeno, un átomo de halógeno o un grupo seleccionado entre un grupo alquilo de C1-C3, un grupo hidroxilo, un grupo -COOR1, un grupo -NO2, un grupo -NR1R2, un grupo morfolinilo o morfolino, un grupo N-metilpiperazinilo, un grupo fluoroalquilo de C1-C3, un grupo alcoxi de C1-C4, y un grupo -CN, Z es N o C, Y es N o C, Z es N o C, W es N o C, T es N o C, U es N o C, para utilizarse como un agente para la prevención, inhibición o tratamiento de afecciones patológicas o no patológicas involucradas con envejecimiento prematuro. Algunos de los compuestos son nuevos y también forman parte de la invención.
MX2015016292A 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria. MX364280B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18655209P 2009-06-12 2009-06-12
US18654409P 2009-06-12 2009-06-12
EP09162630A EP2261214A1 (en) 2009-06-12 2009-06-12 Compounds useful to treat premature aging and in particular progeria
EP20090305540 EP2266972A1 (en) 2009-06-12 2009-06-12 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
PCT/IB2010/052652 WO2010143170A2 (en) 2009-06-12 2010-06-14 Compounds useful for treating premature aging and in particular progeria

Publications (1)

Publication Number Publication Date
MX364280B true MX364280B (es) 2019-04-22

Family

ID=43309298

Family Applications (9)

Application Number Title Priority Date Filing Date
MX2016007353A MX367601B (es) 2009-06-12 2010-06-14 Compuestos útiles para tratar cáncer.
MX2011013122A MX340095B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar sida.
MX2015016293A MX364989B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.
MX2015016292A MX364280B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.
MX2011013120A MX338823B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.
MX2011013119A MX353776B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar cancer.
MX2015016290A MX364282B (es) 2009-06-12 2010-06-14 Compuestos útiles para tratar envejecimiento prematuro y en particular progeria.
MX2015016291A MX364279B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.
MX2016003039A MX359575B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar sida.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2016007353A MX367601B (es) 2009-06-12 2010-06-14 Compuestos útiles para tratar cáncer.
MX2011013122A MX340095B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar sida.
MX2015016293A MX364989B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2011013120A MX338823B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.
MX2011013119A MX353776B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar cancer.
MX2015016290A MX364282B (es) 2009-06-12 2010-06-14 Compuestos útiles para tratar envejecimiento prematuro y en particular progeria.
MX2015016291A MX364279B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.
MX2016003039A MX359575B (es) 2009-06-12 2010-06-14 Compuestos utiles para tratar sida.

Country Status (24)

Country Link
US (7) US20120329796A1 (es)
EP (6) EP2440546B1 (es)
JP (8) JP5905385B2 (es)
KR (14) KR102016889B1 (es)
CN (13) CN109776496B (es)
AU (3) AU2010258294B2 (es)
BR (5) BRPI1010768C8 (es)
CA (5) CA2764024C (es)
CU (4) CU24093B1 (es)
DK (4) DK2440547T3 (es)
ES (3) ES2938532T3 (es)
FI (3) FI3517534T3 (es)
HK (8) HK1173153A1 (es)
HR (3) HRP20230143T1 (es)
HU (2) HUE061262T2 (es)
LT (1) LT2440547T (es)
MX (9) MX367601B (es)
PL (4) PL3517534T3 (es)
PT (4) PT2440546T (es)
RU (1) RU2567752C2 (es)
SI (1) SI2440547T1 (es)
TR (1) TR201910781T4 (es)
WO (3) WO2010143169A2 (es)
ZA (2) ZA201109032B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
WO2010143169A2 (en) * 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids
EP2473504B1 (en) 2009-09-03 2015-02-25 Bioenergenix Heterocyclic compounds for the inhibition of pask
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2661431B1 (en) 2011-01-05 2018-07-11 Bioenergenix Heterocyclic compounds for the inhibition of pask
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
CA2828349C (en) 2011-03-02 2019-05-21 John M. Mccall Heterocyclic compounds for the inhibition of pask
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20150150869A1 (en) * 2012-06-20 2015-06-04 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基－嘧啶衍生物
JP6193374B2 (ja) 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
JP2014237624A (ja) * 2012-10-23 2014-12-18 日本曹達株式会社 ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
US20140194465A1 (en) * 2013-01-04 2014-07-10 Novarx Corporation Compositions for treatment of cancer
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JP6895251B2 (ja) 2013-07-05 2021-06-30 アビバックス レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物
EP3020829B1 (en) * 2013-07-12 2021-11-17 Kyoto University Pharmaceutical composition capable of inhibiting abnormal splicing causative of onset or progress of a genetic disease
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
LT3122359T (lt) 2014-03-26 2021-03-25 Astex Therapeutics Ltd. Fgfr inhibitoriaus ir igf1r inhibitoriaus deriniai
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
ES2857606T3 (es) 2015-01-30 2021-09-29 Centre Nat Rech Scient Isoformas delta133P53beta y delta133P53gamma son biomarcadores de células madre cancerosas
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
ES2811845T3 (es) 2015-09-23 2021-03-15 Janssen Pharmaceutica Nv Heterociclos tricíclicos para el tratamiento del cáncer
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
CA3008107C (en) 2015-12-17 2023-06-27 Biokine Therapeutics Ltd. 8-phenoxy-quinoline derivatives for inhibiting chemokine activity and/or cancer cells growth
AU2017216212B2 (en) * 2016-02-03 2020-12-24 Janssen Pharmaceutica Nv Tau PET imaging ligands
HRP20211779T1 (hr) 2016-03-18 2022-03-04 Prosynergia S.A.R.L. Postupak priprave derivata kinolin-2-il-fenilamina i njihovih soli
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
CN106496061B (zh) * 2016-10-20 2018-06-05 湘潭大学 一种萃取分离酰化反应液中乙酰精胺的方法
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CN110996983A (zh) * 2017-06-26 2020-04-10 巴斯德研究所 清除hiv储库并降低病毒载量的治疗
US10889566B2 (en) 2017-08-29 2021-01-12 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
US20200039989A1 (en) * 2018-03-01 2020-02-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk/clk and uses thereof
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
EP3669874A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
AU2020276793A1 (en) 2019-05-15 2022-01-20 Alonbio Ltd. Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
JP2023532163A (ja) * 2020-01-31 2023-07-27 アビバックス ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの非晶質固体分散物
EP3858336A1 (en) 2020-01-31 2021-08-04 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP3858815A1 (en) 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
AU2021238792A1 (en) 2020-03-20 2022-10-13 Abivax Compounds for treating or preventing a Coronaviridae infection and methods and uses for assessing the occurrence of a Coronaviridae infection
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
JP2024507935A (ja) 2021-02-25 2024-02-21 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としてのスピロ環式ラクタム
EP4063351A1 (en) 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
CN117222639A (zh) 2021-05-27 2023-12-12 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
KR20230072900A (ko) 2021-11-18 2023-05-25 동우 화인켐 주식회사 마이크로 led 구조체 및 이의 제조방법
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023138657A1 (zh) * 2022-01-24 2023-07-27 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR400973A (fr) 1909-03-19 1909-08-13 Jean Victor Massillon Nouveau sertisseur à main pour la fabrication des cartouches
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (es) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) * 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO2000059875A2 (en) * 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
NZ537724A (en) * 2002-07-19 2006-10-27 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (fr) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
WO2005037285A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
US7485643B2 (en) * 2003-11-19 2009-02-03 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
CA2585490A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP1853265B1 (en) 2005-01-28 2016-01-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis
CN101213260A (zh) * 2005-06-29 2008-07-02 株式会社Adeka 树脂添加剂组合物和其树脂组合物
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
MX2009007661A (es) * 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
CA2681481A1 (en) * 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
CN101679150B (zh) * 2007-05-17 2013-05-15 Lg化学株式会社 蒽衍生物和使用该蒽衍生物的有机电子器件
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
JP2010536789A (ja) 2007-08-15 2010-12-02 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する３’置換化合物
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
KR100974562B1 (ko) * 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
CA2747790A1 (en) * 2009-01-05 2010-07-08 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
WO2010079123A2 (en) * 2009-01-06 2010-07-15 Dsm Ip Assets B.V. Process for resveratrol intermediate
KR20110117652A (ko) * 2009-01-06 2011-10-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 동맥경화증의 치료를 위한 ｂ세포 감소 제제
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
WO2010143169A2 (en) * 2009-06-12 2010-12-16 Société Splicos Compounds useful for treating aids
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
JP2016504268A (ja) 2012-10-04 2016-02-12 オヤジェン インコーポレイテッドＯｙａＧｅｎ， Ｉｎｃ． Ｖｉｆの自己会合を撹乱する抗ｈｉｖ剤としての小分子及びその使用方法
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
JP2015120566A (ja) * 2013-12-20 2015-07-02 ニチユ三菱フォークリフト株式会社 荷役車両

Also Published As

Publication number Publication date
US20120283265A1 (en) 2012-11-08
SI2440547T1 (sl) 2023-05-31
PL3517534T3 (pl) 2024-06-24
MX340095B (es) 2016-06-27
KR20180100737A (ko) 2018-09-11
EP2440547B1 (en) 2022-11-30
EP2440545A2 (en) 2012-04-18
EP2440547A2 (en) 2012-04-18
MX338823B (es) 2016-05-03
RU2011149571A (ru) 2013-07-20
CU24245B1 (es) 2017-02-02
EP3517534B1 (en) 2024-02-28
CN106905232A (zh) 2017-06-30
KR101982461B1 (ko) 2019-05-24
CN109776496B (zh) 2021-09-28
CU20150024A7 (es) 2015-09-29
CA2764024A1 (en) 2010-12-16
WO2010143169A2 (en) 2010-12-16
ZA201109031B (en) 2013-02-27
US20120329796A1 (en) 2012-12-27
EP4198022A1 (en) 2023-06-21
AU2010258214A1 (en) 2012-01-19
JP2012529493A (ja) 2012-11-22
CN106928205B (zh) 2019-09-24
PT3517534T (pt) 2024-05-17
CN102596935B (zh) 2015-02-18
ES2938532T3 (es) 2023-04-12
HRP20230143T1 (hr) 2023-03-31
US20140080831A1 (en) 2014-03-20
BRPI1010772B8 (pt) 2021-05-25
KR102016892B1 (ko) 2019-08-30
US20140288120A1 (en) 2014-09-25
AU2010258295A1 (en) 2012-01-19
BRPI1010768A2 (pt) 2016-11-01
KR20120054585A (ko) 2012-05-30
CN102574835A (zh) 2012-07-11
EP3521283A1 (en) 2019-08-07
CN102625804B (zh) 2015-04-08
US9908869B2 (en) 2018-03-06
MX2011013120A (es) 2012-07-23
BRPI1010772A2 (pt) 2016-11-01
KR20170124646A (ko) 2017-11-10
JP2015187152A (ja) 2015-10-29
JP2012529494A (ja) 2012-11-22
EP3517534A1 (en) 2019-07-31
WO2010143170A2 (en) 2010-12-16
EP3521283B1 (en) 2024-02-28
KR20190018570A (ko) 2019-02-22
HK1212702A1 (zh) 2016-06-17
DK3517534T3 (da) 2024-05-27
KR101897221B1 (ko) 2018-09-10
BRPI1012892A2 (pt) 2018-03-13
CA2764026C (en) 2019-10-29
ZA201109032B (en) 2013-02-27
MX364279B (es) 2019-04-22
FI3517534T3 (fi) 2024-05-16
JP6158250B2 (ja) 2017-07-05
US20120277230A1 (en) 2012-11-01
HK1213246A1 (zh) 2016-06-30
MX364989B (es) 2019-05-17
PL2440547T3 (pl) 2023-09-11
CU20110228A7 (es) 2012-04-15
CU24124B1 (es) 2015-08-27
CU24461B1 (es) 2020-01-03
HK1173447A1 (zh) 2013-05-16
KR20180100735A (ko) 2018-09-11
CN104945378A (zh) 2015-09-30
CN102625804A (zh) 2012-08-01
JP7042245B2 (ja) 2022-03-25
CA2965791C (en) 2020-06-09
BRPI1012892B8 (pt) 2021-05-25
HK1200363A1 (en) 2015-08-07
MX2011013122A (es) 2012-07-23
JP5905385B2 (ja) 2016-04-20
EP2440545B1 (en) 2019-04-24
KR20190018571A (ko) 2019-02-22
US20150307478A1 (en) 2015-10-29
CA3070823C (en) 2021-09-21
WO2010143168A3 (en) 2011-06-09
JP2015187150A (ja) 2015-10-29
CN104945379B (zh) 2018-11-30
CN104945379A (zh) 2015-09-30
DK2440546T3 (da) 2023-03-27
CN106928205A (zh) 2017-07-07
KR101982463B1 (ko) 2019-05-24
HK1173153A1 (en) 2013-05-10
US9145367B2 (en) 2015-09-29
CN104844570B (zh) 2018-11-02
KR20190018568A (ko) 2019-02-22
FI2440546T3 (fi) 2023-03-30
KR20120051643A (ko) 2012-05-22
CN106928194B (zh) 2019-11-12
HRP20240582T1 (hr) 2024-07-19
JP2020045342A (ja) 2020-03-26
RU2011149572A (ru) 2013-07-20
KR101863021B1 (ko) 2018-05-30
HK1213247A1 (zh) 2016-06-30
PT2440545T (pt) 2019-07-19
CA2965791A1 (en) 2010-12-16
JP2015155453A (ja) 2015-08-27
JP2012529495A (ja) 2012-11-22
PL2440545T3 (pl) 2019-11-29
KR101789275B1 (ko) 2017-11-20
MX2011013119A (es) 2012-07-04
CN104844510B (zh) 2019-04-23
KR20180101727A (ko) 2018-09-13
CA2764024C (en) 2017-12-05
KR20190018567A (ko) 2019-02-22
KR101982462B1 (ko) 2019-05-24
ES2940885T3 (es) 2023-05-12
BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B8 (pt) 2020-03-10
JP6041671B2 (ja) 2016-12-14
KR20190018569A (ko) 2019-02-22
MX359575B (es) 2018-10-03
CN106928194A (zh) 2017-07-07
DK2440547T3 (da) 2023-02-20
CA2764027A1 (en) 2010-12-16
AU2010258294B2 (en) 2015-07-30
BRPI1010768C8 (pt) 2020-04-07
JP5826745B2 (ja) 2015-12-02
PT2440546T (pt) 2023-03-27
EP2440546A2 (en) 2012-04-18
KR102016890B1 (ko) 2019-08-30
FI2440547T3 (fi) 2023-03-14
BRPI1012892B1 (pt) 2020-10-27
EP2440546B1 (en) 2022-12-28
CN104844510A (zh) 2015-08-19
CN104945378B (zh) 2018-11-20
KR101769616B1 (ko) 2017-08-18
DK2440545T3 (da) 2019-07-22
BRPI1010772B1 (pt) 2020-10-27
PT2440547T (pt) 2023-02-17
CN102596935A (zh) 2012-07-18
WO2010143169A3 (en) 2011-11-10
HK1173726A1 (zh) 2013-05-24
WO2010143168A2 (en) 2010-12-16
TR201910781T4 (tr) 2019-08-21
US10017498B2 (en) 2018-07-10
JP6158251B2 (ja) 2017-07-05
BR122019013686B1 (pt) 2020-03-17
MX367601B (es) 2019-08-28
ES2736198T3 (es) 2019-12-26
AU2010258294A1 (en) 2012-01-19
KR102016893B1 (ko) 2019-08-30
CU20110229A7 (es) 2012-06-21
AU2010258214B2 (en) 2015-08-20
CU24093B1 (es) 2015-04-29
US9108919B2 (en) 2015-08-18
BR122019013687B1 (pt) 2020-04-14
CN109776496A (zh) 2019-05-21
CN106905232B (zh) 2019-09-27
WO2010143170A3 (en) 2011-08-11
MX364282B (es) 2019-04-22
CN104844570A (zh) 2015-08-19
HUE045548T2 (hu) 2019-12-30
JP2015187151A (ja) 2015-10-29
KR101973348B1 (ko) 2019-04-26
KR20180100736A (ko) 2018-09-11
CA3070823A1 (en) 2010-12-16
US20150299129A1 (en) 2015-10-22
RU2567752C2 (ru) 2015-11-10
KR20120049860A (ko) 2012-05-17
KR102016891B1 (ko) 2019-08-30
US9637475B2 (en) 2017-05-02
CN103948594A (zh) 2014-07-30
KR20170092720A (ko) 2017-08-11
KR102016889B1 (ko) 2019-08-30
AU2010258295B2 (en) 2015-09-03
CA2764027C (en) 2020-11-03
CN103948594B (zh) 2016-10-26
HK1212990A1 (zh) 2016-06-24
PL2440546T3 (pl) 2023-07-10
HRP20230248T1 (hr) 2023-04-14
BRPI1010768B1 (pt) 2019-10-22
CU20110230A7 (es) 2012-04-15
CN113004249A (zh) 2021-06-22
LT2440547T (lt) 2023-03-10
MX353776B (es) 2018-01-29
CN102574835B (zh) 2014-04-16
HUE061262T2 (hu) 2023-05-28
CA2764026A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
MX364989B (es) Compuestos utiles para tratar envejecimiento prematuro y en particular progeria.
MX2019008390A (es) Compuestos utiles para tratar cancer.
TW200641539A (en) Salt suitable for an acid generator and a chemically amplified resist composition containing the same
TW200719089A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
TW200731013A (en) Salt suitable for an acid generator and a chemically amplified resist composition containing the same
TW200641530A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
TW200728914A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
MXPA05012033A (es) Compuesto de pirimidina y composicion para el control de plagas que contiene el mismo.
MX2009005731A (es) Composicion antimicrobiana para acabado de textiles.
TW200704640A (en) Pyrazolecarboxamides
NI200900164A (es) COMPUESTOS AMINO- 5 -[ -4- (DIFLUOROMETOXI) FENIL SUSTITUIDO] -5- FENILIMIDAZOLONA COMO INHIBIDORES DE Beta - SECRETASA.
MD20110063A2 (en) Herbicidal compositions containing benzoylpyrazole compounds
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
IL195766A (en) Phosphinic acids and their sulfur derivatives, methods for their preparation and use as metal extraction materials
TW200640928A (en) 5,6-Dialkyl-7-aminoazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds
MX2013005179A (es) Derivado de pirazino[2,3-d]isoxazol.
MX2022014200A (es) Derivado de 1,4,5,6-tetrahidropirimidin-2-amina.
TW200700370A (en) Producing method of haloalkylether compounds
WO2013175498A3 (en) Amido-amine and glycerol based compound and process of preparation
EP1873143B8 (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
TW200738722A (en) Method for producing imidazo[1,2-b]pyridazine compound
SG165309A1 (en) Process for producing 3-methylthiopropanal
TW200510336A (en) Pyrimidine compound and arthropod controlling composition containing the same
TH115253B (th) สารอนุพันธ์ของเบนโซไธอะซีน, การเตรียมสารอนุพันธ์นี้และการใช้สารอนุพันธ์นี้เป็นยา
TH114114B (th) กรดฟอสฟินิคชนิดใหม่ และอนุพันธ์ซัลเฟอร์ของมันและวิธีการสำหรับการเตรียมของมัน